Y-mAbs Therapeutics’ (YMAB) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB) in a research report sent to investors on Friday,Benzinga reports. They currently have a $22.00 price target on the stock.

Several other equities analysts also recently weighed in on the stock. Canaccord Genuity Group raised shares of Y-mAbs Therapeutics to a “strong-buy” rating in a report on Tuesday, August 13th. Canaccord Genuity Group reiterated a “buy” rating and issued a $26.00 price target on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 13th. Cantor Fitzgerald restated an “overweight” rating and issued a $20.00 price objective on shares of Y-mAbs Therapeutics in a research report on Monday, September 9th. BMO Capital Markets dropped their price objective on Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating for the company in a research note on Tuesday, August 13th. Finally, Wedbush reissued an “outperform” rating and set a $23.00 target price on shares of Y-mAbs Therapeutics in a research note on Tuesday, September 10th. One investment analyst has rated the stock with a sell rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Y-mAbs Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $21.14.

Y-mAbs Therapeutics Price Performance

Shares of Y-mAbs Therapeutics stock opened at $11.14 on Friday. The stock has a market capitalization of $498.96 million, a PE ratio of -20.63 and a beta of 0.68. Y-mAbs Therapeutics has a 1-year low of $5.04 and a 1-year high of $20.90. The company’s fifty day simple moving average is $13.98 and its 200-day simple moving average is $13.05.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings results on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The company had revenue of $18.46 million for the quarter, compared to the consensus estimate of $23.38 million. During the same period in the prior year, the firm posted ($0.18) EPS. As a group, research analysts anticipate that Y-mAbs Therapeutics will post -0.64 EPS for the current year.

Insiders Place Their Bets

In other news, insider Thomas Gad sold 65,000 shares of the business’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $13.47, for a total value of $875,550.00. Following the sale, the insider now directly owns 97,681 shares in the company, valued at $1,315,763.07. The trade was a 39.96 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Joris Wilms sold 5,000 shares of Y-mAbs Therapeutics stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $14.69, for a total value of $73,450.00. Following the completion of the transaction, the chief operating officer now owns 30,600 shares of the company’s stock, valued at approximately $449,514. This represents a 14.04 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 100,000 shares of company stock valued at $1,338,100 in the last quarter. 22.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Large investors have recently made changes to their positions in the company. Caligan Partners LP raised its position in Y-mAbs Therapeutics by 105.3% in the 3rd quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock worth $15,718,000 after purchasing an additional 613,175 shares during the period. State Street Corp lifted its stake in shares of Y-mAbs Therapeutics by 50.4% during the 3rd quarter. State Street Corp now owns 1,209,781 shares of the company’s stock worth $15,909,000 after acquiring an additional 405,169 shares during the last quarter. Squarepoint Ops LLC lifted its stake in shares of Y-mAbs Therapeutics by 143.4% during the 2nd quarter. Squarepoint Ops LLC now owns 126,389 shares of the company’s stock worth $1,527,000 after acquiring an additional 74,452 shares during the last quarter. Millennium Management LLC boosted its holdings in Y-mAbs Therapeutics by 23.8% during the 2nd quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock valued at $4,225,000 after acquiring an additional 67,233 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in Y-mAbs Therapeutics by 15.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock valued at $5,853,000 after acquiring an additional 65,732 shares during the last quarter. 70.85% of the stock is owned by hedge funds and other institutional investors.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.